Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; ERBB2 Overexpression; HER2 Positive Breast Carcinoma; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Refractory Breast Carcinoma Interventions: Drug: Alpha-tocopheryloxyacetic Acid; Biological: Trastuzumab Sponsors: University of Washington; National Cancer Institute (NCI); Veana Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Herceptin | Research